Overview

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to generate evidence demonstrating the domain specification via modern psychometric methods, reliability, validity, and responsiveness of Quality of Life - Bronchiectasis (QoL-B) and Patient-Reported Outcome Measurement Information System - Fatigue-Short Form (PROMIS F-SF 7a) in participants with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by Myobaxterium avium Complex (MAC).

Phase:

Phase 3

Details

Lead Sponsor:

Insmed Incorporated

Treatments:

Amikacin
Azithromycin
Ethambutol